Controversial New Alzheimer's Drug: What to Know

1 week ago 18
aducanumab

As the archetypal Alzheimer's cause approved since 2003, advocates applaud the decision. Critics accidental the support was based connected inadequate impervious that the cause works and balk astatine the terms tag of $56,000 a year.

Read Entire Article